2 active not recruiting, 2 completed, 2 recruiting, 2 withdrawn. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Active not recruiting 2, Completed 2, Recruiting 2, Withdrawn 2, Not yet recruiting 1, Terminated 1 |
Follow Urothelial Carcinoma Bladder: new trials by email Literature Review of Urothelial Carcinoma Bladder trials Research Report on Urothelial Carcinoma Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Withdrawn | Relmada Therapeutics, Inc. | 2026-06-30 | 2026-03-17 | |
| A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 | Withdrawn | Relmada Therapeutics, Inc. | 2026-05-01 | 2026-03-17 | |
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer UGN-103 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Completed | UroGen Pharma Ltd. | 99 | 2024-08-29 | 2026-10-22 |
| Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE - Bladder Cancer, Bladder Cancer Recurrent | Phase 3 | Recruiting | Verity Pharmaceuticals Inc. | 540 | 2024-04-24 | 2026-03-20 |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UGN-102 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Active not recruiting | UroGen Pharma Ltd. | 240 | 2022-03-01 | 2026-05-11 |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) UGN-102 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Completed | UroGen Pharma Ltd. | 8 | 2021-11-30 | 2024-09-19 |
| A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer UGN-102, TURBT - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Terminated | UroGen Pharma Ltd. | 282 | 2021-02-19 | 2024-06-06 |
| Bladder Cancer Adjuvant Radiotherapy Trial Adjuvant RT - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 3 | Active not recruiting | Tata Memorial Centre | 153 | 2016-06-02 | 2025-02-13 |
Urinary Bladder Neoplasms (9) · Non-Muscle Invasive Bladder Neoplasms (6) · Carcinoma, Transitional Cell (4) · Neoplasms (4) · Urologic Neoplasms (3) · Neoplasm Metastasis (1) · Recurrence (1)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Male Urogenital Diseases (10) · Neoplasms by Site (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Urologic Diseases (10) · Urinary Bladder Diseases (9) · Urologic Neoplasms (7) · Carcinoma (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Mitomycin (4) · BCG Vaccine (1) · Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · Platinum Compounds (1)
UroGen Pharma Ltd. (4) · Relmada Therapeutics, Inc. (3) · SystImmune Inc. (1) · Tata Memorial Centre (1) · Verity Pharmaceuticals Inc. (1)
United States (5) · Bulgaria (3) · Estonia (3) · Georgia (3) · Latvia (3) · Poland (2) · Serbia (2) · Spain (2) · Austria (1) · Canada (1) · India (1) · Israel (1) · Lithuania (1) · Romania (1) · Russia (1)
Sandip Prasad, MD (2) · Alexandre R Zlotta, MD, PhD, FRCSC (1) · Girish S Kulkarni, MD (1) · Jimmy Liu Zhao, MD, PhD (1) · Joao P Zambon, MD (1) · Raj S Pruthi, MD MHA (1) · Raj S Pruthi, MD MHA FACS (1) · Sebastian Mirkin, MD (1) · Sunil Raju, MBBS (1)
PMID 37468392, PMID 37548555, PMID 38265030, PMID 39353477, PMID 39446087, PMID 40048558, PMID 41880645, PMID 42166701